| Title | Boosting innate and adaptive antitumor immunity via a biocompatible and carrier-free nanovaccine engineered by the bisphosphonates-metal coordination |
| Authors | Qin, Mengmeng Li, Minghui Song, Ge Yang, Canyu Wu, Peiyao Dai, Wenbing Zhang, Hua Wang, Xueqing Wang, Yiguang Zhou, Demin He, Bing Zhang, Qiang |
| Affiliation | Peking Univ, Sch Pharmaceut Sci, Beijing Key Lab Mol Pharmaceut & New Drug Deliver, Beijing 100191, Peoples R China Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China |
| Keywords | DELTA T-CELLS CANCER VACCINES DENDRITIC CELLS COMBINATION IMMUNOTHERAPY ACTIVATION DELIVERY |
| Issue Date | Apr-2021 |
| Publisher | NANO TODAY |
| Abstract | Most of tumor vaccines currently focus on inducing adaptive immunity, while the antitumor potential of innate immunity is getting more attentions. In an attempt to recruit both innate and adaptive immunity, bisphosphonates (BPs) as a type of orthopaedics drugs with biosafety was applied in an antitumor vaccine here as an innate immune regulator. BPs and calcium themselves shaped the biodegradable nanocarrier via their coordination (CaBPs), which could load peptide antigens due to its hydrophilicity and be stabilized by surface lipids including a TLR4 agonist (nanovaccine). As results, the incorporation of BPs triggered the proliferation and activation of DCs and innate-like gamma delta T cells, while the nanovaccine enhanced antigen presentation and specific lysis of tumor cells. The combination of nanovaccine and anti-PD-1 achieved a 50% total disappearance of tumor. In a prophylactic study, no any tumor occurred in nanovaccine group during a 110 day study with 3 time tumor challenges. Generally, this study validates the double antitumor immunities and provides a very promising approach for clinic application. (C) 2021 Elsevier Ltd. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/612836 |
| ISSN | 1748-0132 |
| DOI | 10.1016/j.nantod.2021.101097 |
| Indexed | EI SCI(E) |
| Appears in Collections: | 药学院 天然药物与仿生药物国家重点实验室 |
